Please login to the form below

Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019

For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress

For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress from 2nd November to 6th November, 2019. Our team of Market Access, Pricing and HEOR experts will be available throughout the event at booth C2-006 which will be held in Copenhagen, Denmark.

If you would like to book a meeting, at the event, with one of our experts and learn more about how best to challenge your market access barriers, please contact us via discover@validinsight.com.

22nd October 2019

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to get a return on investment.  What are the implications for pharma and biotech market access?
Valid Insight
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step.
Valid Insight
How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement.
Valid Insight
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.
Valid Insight
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.
Valid Insight